IP Library Granted Patent US 10,047,165
Granted Patent B2
US 10,047,165 · App. 15/263,876 · Granted Aug 14, 2018

Compositions for inhibiting MASP-2 dependent complement activation

Inventors: Thomas Dudler (Bellevue, WA); Wayne R. Gombotz (Kenmore, WA); James Brian Parent (Bainbridge Island, WA); Clark E. Tedford (Poulsbo, WA); Anita Kavlie (Oslo, NO); Urs Beat Hagemann (Oslo, NO); Herald Reiersen (Sofiemyr, NO); Sergej Kiprijanov (Olso, NO)
Assignee: Omeros Corporation
C07K16/40C12N9/6424C12Y304/21104A61K2039/505C07K2317/21C07K2317/33C07K2317/53C07K2317/54C07K2317/55C07K2317/56C07K2317/565C07K2317/622C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,165
App. No.
15/263,876
Granted
Aug 14, 2018
Kind
B2
Abstract

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Claims (11)

1. A nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy and light chain variable regions comprise the amino acid sequences set forth in SEQ ID NO:20 and SEQ ID NO:24, respectively.

2. A nucleic acid comprising a nucleotide sequence encoding heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy and light chain variable regions, comprise the amino acid sequences set forth in SEQ ID NO:20 and SEQ ID NO:24, respectively.

3. An expression vector comprising the nucleic acid according to claim 1 or claim 2 .

4. A cell comprising the expression vector according to claim 3 .

5. A method for producing an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, the method comprising culturing the cell of claim 4 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoding by the nucleic acid.

6. The method of claim 5 , further comprising isolating the antibody, or antigen-binding fragment thereof.

7. A cell comprising:

(a) a nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:20; and

(b) a nucleic acid encoding complementarity determining regions (CDRs) of a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:24.

8. A method for producing an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, the method comprising culturing the cell of claim 7 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid.

9. The method of claim 8 , further comprising isolating the antibody, or antigen-binding fragment thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 25, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: OMEROS CORPORATION
Reel/Frame 073705/0970 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE BOX TITLED"THIS DOCUMENT SERVES AS AN OATH/DECLARATION (37 CFR 1.63)" WAS ERRONEOUSLY CHECKED AND THIS BOX SHOULD NOT HAVE BEEN CHECKED, PREVIOUSLY RECORDED AT REEL: 67607 FRAME: 108. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Dec 11, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 069715/0719 →
SECURITY INTEREST Recorded Jun 3, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 067607/0108 →
RELEASE OF SECURITY INTEREST Recorded Nov 15, 2018
From: CRG SERVICING LLC
To: OMEROS CORPORATION
Reel/Frame 047573/0577 →
SECURITY INTEREST Recorded Nov 7, 2016
From: OMEROS CORPORATION
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040575/0110 →
Continuity (4)
Division 14660040 · Mar 17, 2015
Division 13464334 · May 4, 2012
Provisional Application 61482567 · May 4, 2011
Related Publication 20170088632A1 · Mar 30, 2017